Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141552

Published: 2020

Journal Articles

Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration

Ingrid Karlsson, PhD, Linda Mårtensson, PhD, Marie Borggren, PhD, Mathilda Kovacek, Carl Roos, Therese Blidberg, Robert Oldham, PhD, Mats Jerkeman, MD PhD, Martin J.S. Dyer, MD PhD, Andrew Davies, MD PhD, Raul Córdoba, MD PhD, Pau Abrisqueta, MD PhD, Stephen Beers, PhD, Ingrid Teige, PhD, Andres McAllister, MD PhD, Sean H Lim, MD PhD, Mark S Cragg, PhD, Björn Frendéus, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138658

Published: 2020

Journal Articles

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment

Anna H Turaj, MSc, Vikki L Field, Claude H.T. Chan, PhD, Christine A. Penfold, BSc, Jinny H. Kim, PhD, Sonya James, PhD, Kerry L Cox, Tibor Keler, PhD, Peter M Johnson, MA, MD, Aymen Al-Shamkhani, PhD, Stephen A Beers, PhD, Martin J. Glennie, PhD, Mark S Cragg, PhD, Sean H Lim, MD PhD

Blood (2016) 128 (22): 3024.

https://doi.org/10.1182/blood.V128.22.3024.3024

Published: 2016

Journal Articles

PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis

Matthew J Carter, PhD, Kerry L Cox, Stuart J Blakemore, Anna H Turaj, MSc, Robert J Oldham, Lekh N. Dahal, PhD, Stacey Tannheimer, Francesco Forconi, MD DM, PhD FRCPath, Graham Packham, PhD, Mark S Cragg, PhD

Blood (2016) 128 (22): 3241.

https://doi.org/10.1182/blood.V128.22.3241.3241

Published: 2016

Journal Articles

Chemical Activation of the SHIP1 Inositol Lipid Phosphatase: A Novel Therapeutic Strategy to Suppress B-Cell Receptor Signaling and CXCR4 Expression in Malignant Human B Cells

Graham Packham, PhD, Beatriz Valle-Argos, Elizabeth Lemm, Lindsay D Smith, PhD, Nicola J Weston-Bell, PhD, Yohannes Gebreselassie, Andrew J Steele, PhD, Freda K Stevenson, Mark S Cragg, PhD, Francesco Forconi, MD DM, PhD FRCPath, Jennifer Cross, Curtis Harwig, Lloyd Mackenzie

Blood (2016) 128 (22): 2037.

https://doi.org/10.1182/blood.V128.22.2037.2037

Published: 2016

Journal Articles

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

Jennifer Edelmann, MD, Tetyana Klymenko, PhD, Chen Lu, PhD, Emma Vilventhraraja, Sven Estenfelder, Eugen Tausch, Stephen A Beers, PhD, Stephan Stilgenbauer, Mark S Cragg, PhD, Andrejs Ivanov, PhD, John Gribben

Blood (2016) 128 (22): 971.

https://doi.org/10.1182/blood.V128.22.971.971

Published: 2016

Journal Articles

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Anna Kretschmer, Stefan Lohse, PhD, Thies Rösner, PhD, Marco J.H. Jansen, Christian Kellner, PhD, Matthias Peipp, PhD, Mark S Cragg, PhD, Ameera Alsadeq, PhD, Denis M Schewe, MD, Jeanette H.W. Leusen, PhD, Thomas Valerius, MD

Blood (2016) 128 (22): 1835.

https://doi.org/10.1182/blood.V128.22.1835.1835

Published: 2016

Journal Articles

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Blood (2015) 126 (23): 365.

https://doi.org/10.1182/blood.V126.23.365.365

Published: 2015

Journal Articles

Biological Significance of B Cell Receptor Mediated Regulation of Autophagy in Chronic Lymphocytic Leukemia

Lindsay Smith, PhD, Elizabeth Hogg, BSc(Hons), Angus Haynes, Jonathan C Strefford, PhD, Francesco Forconi, MD DM, PhD FRCPath, Freda K Stevenson, DPhil, Graham Packham, PhD, Mark S Cragg, PhD, David Tumbarello, Matthew D Blunt, PhD, Andrew J Steele, PhD

Blood (2015) 126 (23): 4130.

https://doi.org/10.1182/blood.V126.23.4130.4130

Published: 2015

Journal Articles

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Matthew A Care, PhD, Stephen M Thirdborough, PhD, Andrew J Davies, MRCP PhD, Peter W.M. Johnson, FRCP, Andrew Jack, PhD MB, Sharon Barrans, PhD, David R Westhead, PhD, Mark S Cragg, PhD, Reuben M Tooze, PhD FRCP, Stephen A Beers, PhD

Blood (2015) 126 (23): 2663.

https://doi.org/10.1182/blood.V126.23.2663.2663

Published: 2015

Journal Articles

The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Matthew D Blunt, PhD, Jack Parnell, BSc(hons), Marta Larrayoz, PhD, Lindsay Smith, PhD, Rachel Dobson, BSc(Hons), Jonathan C Strefford, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Andrew J Davies, MRCP, Peter W Johnson, MD, Graham Packham, PhD, Greg P. Coffey, PhD, Mark S Cragg, PhD, Andrew J Steele, PhD

Blood (2015) 126 (23): 1716.

https://doi.org/10.1182/blood.V126.23.1716.1716

Published: 2015

Journal Articles

Expression of Inhibitory Fc Receptor (FcγRIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL).

Chern Siang Lee, MB BS, Margaret Ashton-Key, MD FRCPath, Sergio Cogliatti, Susanne Crowe, Mark S Cragg, PhD, Shu-Fang H Schmitz, Michele Ghielmini, MD, Peter Johnson

Blood (2012) 120 (21): 2747.

https://doi.org/10.1182/blood.V120.21.2747.2747

Published: 2012

Journal Articles

Antibody-Induced Non-Apoptotic Cell Death in Human Lymphoma and Leukemia Cells Is Mediated Through NADPH Oxidase-Derived Reactive Oxygen Species

Jamie Honeychurch, PhD, Waleed Alduaij, MRes, Eleanor Cheadle, PhD, Mahsa Azizyan, MSc, Helene Pelicano, PhD, Peng Huang, MD PhD, Andrei Ivanov, MD PhD, Mark S Cragg, PhD, Timothy M Illidge, MD, PhD

Blood (2011) 118 (21): 1651.

https://doi.org/10.1182/blood.V118.21.1651.1651

Published: 2011

Journal Articles

New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.

Waleed Alduaij, MRes, Sandeep Potluri, BA, Andrei Ivanov, PhD, Jamie Honeychurch, PhD, Stephen A Beers, PhD, Claude Chan, PhD, Kazayuki Shimada, MD, Martin J. Glennie, PhD, Mark S Cragg, PhD, Tim Illidge, MD, PhD

Blood (2009) 114 (22): 725.

https://doi.org/10.1182/blood.V114.22.725.725

Published: 2009

Journal Articles

Treatment with the Anti-CD20 Antibody (B1) and Irradiation Result in Synergistic Cytotoxicity That Is Dependent on MAPK Activation.

Andrei Ivanov, MD, Mark S. Cragg, PhD, Tim M. Illidge, MD, PhD

Blood (2006) 108 (11): 2508.

https://doi.org/10.1182/blood.V108.11.2508.2508

Published: 2006

Journal Articles

Bim Is the Critical, and Bad and Bmf Are the Ancillary BH3-Only Proteins for Imatinib Mesylate-Induced Apoptosis of Bcr/Abl-Positive Leukemias.

Junya Kuroda, PhD, MD, Hamsa Puthalakath, PhD, Philippe Bouillet, PhD, Mark S. Cragg, PhD, Priscilla N. Kelly, Andrew W. Roberts, PhD, MD, Shinya Kimura, PhD, MD, Oliver G. Ottmann, PhD, MD, Andreas Strasser, PhD

Blood (2005) 106 (11): 2876.

https://doi.org/10.1182/blood.V106.11.2876.2876

Published: 2005

NARROW

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment

PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis

Chemical Activation of the SHIP1 Inositol Lipid Phosphatase: A Novel Therapeutic Strategy to Suppress B-Cell Receptor Signaling and CXCR4 Expression in Malignant Human B Cells

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia

Biological Significance of B Cell Receptor Mediated Regulation of Autophagy in Chronic Lymphocytic Leukemia

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Expression of Inhibitory Fc Receptor (FcγRIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL).

Antibody-Induced Non-Apoptotic Cell Death in Human Lymphoma and Leukemia Cells Is Mediated Through NADPH Oxidase-Derived Reactive Oxygen Species

New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.

Treatment with the Anti-CD20 Antibody (B1) and Irradiation Result in Synergistic Cytotoxicity That Is Dependent on MAPK Activation.

Bim Is the Critical, and Bad and Bmf Are the Ancillary BH3-Only Proteins for Imatinib Mesylate-Induced Apoptosis of Bcr/Abl-Positive Leukemias.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only